Analysis links GLP-1 receptor agonists to lower macular degeneration risk in older adults

A new analysis of electronic health records found that adults aged 60 and older with obesity and no diabetes who started a GLP-1 receptor agonist were less likely to be diagnosed with age-related macular degeneration (AMD) than similar adults who started another weight-loss medication ^[1]. The study, a target trial emulation, was published May 25, 2026, in Diabetes, Obesity and Metabolism ^[1].

The researchers drew on the TriNetX global health research network, using records from January 2014 through June 2025 ^[1]. They identified new users of GLP-1 receptor agonists and new users of other weight-loss drugs. Everyone in the study was at least 60 years old, had obesity, and did not have diabetes ^[1]. After matching the two groups 1:1 on propensity scores, the analysis included 157,880 patients, or 78,940 per group ^[1].

Over a maximum observation window of seven years, GLP-1 use was associated with a lower risk of incident AMD, with a hazard ratio of 0.82 (95% CI 0.68–0.98) ^[1]. A hazard ratio below 1.0 means fewer AMD diagnoses in the GLP-1 group. Subtype analyses found a lower risk for unspecified AMD (HR 0.70; 95% CI 0.52–0.93) and a trend toward lower risk of nonexudative AMD (HR 0.78; 95% CI 0.60–1.00; p = 0.050) ^[1]. Subgroup results suggested stronger associations in women and in adults aged 60 to 69, which the authors describe as exploratory ^[1].

Two features of the design limit how the result can be read. Follow-up was much shorter in the GLP-1 group, a median of 1.11 years (IQR 1.48) versus 2.56 years (IQR 3.89) for the comparator group ^[1]. AMD develops slowly, so a shorter observation period in one group can distort the comparison. In addition, the main analysis treated GLP-1 receptor agonists as a single class rather than reporting results for individual molecules ^[1]. A sensitivity analysis excluding tirzepatide, the molecule in Mounjaro and Zepbound, is listed in the paper's supporting information, but its results are not given in the abstract ^[1]. The paper also lists sensitivity analyses using a one-year lag between exposure and outcome, a 10-year follow-up, participants with HbA1c below 5.7 percent, and exclusion of prior antidiabetic medication use; those results are likewise not in the abstract ^[1].

The authors state that whether the association reflects direct GLP-1 neuroprotective mechanisms in the retina, greater weight loss, or both remains to be determined, and they call for further mechanistic research and prospective clinical trials ^[1]. They declare no conflicts of interest ^[1]. AMD is a leading cause of irreversible vision loss in older adults, and obesity is a risk factor for the condition, according to research cited in the paper ^[1].

Why it matters for patients

The comparison here is between one group of weight-loss drugs and another, not between a GLP-1 drug and no treatment, so the result does not show how GLP-1 use compares with taking nothing. AMD is a common cause of vision loss in this age group, which makes any signal about risk worth following, but an observational analysis of health records can show an association, not cause and effect ^[1]. Unmeasured differences between the two groups of patients could account for part of the gap.

The study also does not answer several practical questions. It does not report results by individual product, so nothing here distinguishes Ozempic or Wegovy (semaglutide) from Mounjaro or Zepbound (tirzepatide) ^[1]. It says nothing about whether these drugs affect the progression of AMD in people who already have it, and it enrolled only people with obesity and without diabetes, so it does not speak to people taking a GLP-1 drug for type 2 diabetes or at a lower body weight. Those questions have not been reported.

What happens next

The paper's conclusion calls for prospective clinical trials and further work on mechanisms ^[1]. No specific trial, sponsor, start date, or regulatory action has been announced.